These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 30071295)

  • 1. Phase 1-2 Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients With High-Risk Prostate Cancer (SATURN): Early Toxicity and Quality of Life.
    Musunuru HB; D'Alimonte L; Davidson M; Ho L; Cheung P; Vesprini D; Liu S; Chu W; Chung H; Ravi A; Deabreu A; Zhang L; Commisso K; Loblaw A
    Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1438-1447. PubMed ID: 30071295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the Tolerability of a Simultaneous Focal Boost to the Gross Tumor in Prostate SABR: A Toxicity and Quality-of-Life Comparison of Two Prospective Trials.
    Alayed Y; Davidson M; Liu S; Chu W; Tseng E; Cheung P; Vesprini D; Cheung H; Morton G; Musunuru HB; Ravi A; Korol R; Deabreu A; Ho L; Commisso K; Bhounr Z; D'Alimonte L; Mittmann N; Dragomir A; Zhang L; Loblaw A
    Int J Radiat Oncol Biol Phys; 2020 May; 107(1):136-142. PubMed ID: 31987962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SABR in High-Risk Prostate Cancer: Outcomes From 2 Prospective Clinical Trials With and Without Elective Nodal Irradiation.
    Alayed Y; Cheung P; Vesprini D; Liu S; Chu W; Chung H; Musunuru HB; Davidson M; Ravi A; Ho L; Deabreu A; D'Alimonte L; Bhounr Z; Zhang L; Commisso K; Loblaw A
    Int J Radiat Oncol Biol Phys; 2019 May; 104(1):36-41. PubMed ID: 30445172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.
    McCammon R; Rusthoven KE; Kavanagh B; Newell S; Newman F; Raben D
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):413-20. PubMed ID: 19362783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
    Lim TS; Cheung PC; Loblaw DA; Morton G; Sixel KE; Pang G; Basran P; Zhang L; Tirona R; Szumacher E; Danjoux C; Choo R; Thomas G
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):85-92. PubMed ID: 18355982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of a Dose-Escalated Stereotactic Body Radiation Phase 1 Trial for Patients With Low- and Intermediate-Risk Prostate Cancer.
    Potters L; Rana Z; Lee L; Cox BW
    Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):334-342. PubMed ID: 30721721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
    Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogenous Dose-escalated Prostate Stereotactic Body Radiation Therapy for All Risk Prostate Cancer: Quality of Life and Clinical Outcomes of an Institutional Pilot Study.
    Parsai S; Juloori A; Sedor G; Reddy CA; Thousand R; Magnelli A; Berglund RK; Stovsky M; Klein EA; Tendulkar RD; Stephans KL
    Am J Clin Oncol; 2020 Jul; 43(7):469-476. PubMed ID: 32349020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous Focal Boost With Stereotactic Radiation Therapy for Localized Intermediate- to High-Risk Prostate Cancer: Primary Outcomes of the SPARC Phase 2 Trial.
    Yasar B; Suh YE; Chapman E; Nicholls L; Henderson D; Jones C; Morrison K; Wells E; Henderson J; Meehan C; Sohaib A; Taylor H; Tree A; van As N
    Int J Radiat Oncol Biol Phys; 2024 Sep; 120(1):49-58. PubMed ID: 38499253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.
    Herrera FG; Valerio M; Berthold D; Tawadros T; Meuwly JY; Vallet V; Baumgartner P; Thierry AC; De Bari B; Jichlinski P; Kandalaft L; Coukos G; Harari A; Bourhis J
    Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):320-334. PubMed ID: 30267761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical application of high-dose, image-guided intensity-modulated radiotherapy in high-risk prostate cancer.
    Bayley A; Rosewall T; Craig T; Bristow R; Chung P; Gospodarowicz M; Ménard C; Milosevic M; Warde P; Catton C
    Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):477-83. PubMed ID: 19733014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.
    Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Thomas G; Kiss A; Mamedov A; Deabreu A
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):898-905. PubMed ID: 21237581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 2 Multicenter Trial of Heterogeneous-dosing Stereotactic Body Radiotherapy for Low- and Intermediate-risk Prostate Cancer: 5-year Outcomes.
    Fuller DB; Falchook AD; Crabtree T; Kane BL; Medbery CA; Underhill K; Gray JR; Peddada A; Chen RC
    Eur Urol Oncol; 2018 Dec; 1(6):540-547. PubMed ID: 31158102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07).
    Vaugier L; Palpacuer C; Rio E; Goineau A; Pasquier D; Buthaud X; De Laroche G; Beckendorf V; Sargos P; Créhange G; Pommier P; Loos G; Hasbini A; Latorzeff I; Silva M; Denis F; Lagrange JL; Campion L; Supiot S
    Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1061-1067. PubMed ID: 30557672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/IIa trial of androgen deprivation therapy, external beam radiotherapy, and stereotactic body radiotherapy boost for high-risk prostate cancer (ADEBAR).
    Kim YJ; Ahn H; Kim CS; Kim YS
    Radiat Oncol; 2020 Oct; 15(1):234. PubMed ID: 33032643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective Phase II Trial of Once-weekly Hypofractionated Radiation Therapy for Low-risk Adenocarcinoma of the Prostate: Late Toxicities and Outcomes.
    Zimmermann M; Taussky D; Menkarios C; Vigneault É; Beauchemin MC; Bahary JP; Martin AA; Diaz de Bedoya LV; Lambert C
    Clin Oncol (R Coll Radiol); 2016 Jun; 28(6):386-92. PubMed ID: 26782838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT).
    Alayed Y; Quon H; Ong A; Cheung P; Chu W; Chung H; Vesprini D; Chowdhury A; Panjwani D; Pang G; Korol R; Davidson M; Ravi A; McCurdy B; Zhang L; Mamedov A; Deabreu A; Loblaw A
    Radiother Oncol; 2020 Aug; 149():8-13. PubMed ID: 32416376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trial.
    Ong WL; Cheung P; Chung H; Chu W; Detsky J; Liu S; Morton G; Szumacher E; Tseng CL; Vesprini D; Davidson M; Ravi A; McGuffin M; Zhang L; Mamedov A; Deabreu A; Kulasingham-Poon M; Loblaw A
    Radiother Oncol; 2023 Apr; 181():109503. PubMed ID: 36754232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, toxicity and quality of life.
    Musunuru HB; Cheung P; Vesprini D; Liu SK; Chu W; Chung HT; Morton G; Deabreu A; Davidson M; Ravi A; Helou J; Ho L; Zhang L; Loblaw A
    Radiother Oncol; 2021 Aug; 161():40-46. PubMed ID: 34089752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 Trial of Stereotactic Body Radiation Therapy Neoadjuvant to Radical Prostatectomy for Patients With High-Risk Prostate Cancer.
    Parikh NR; Kishan AU; Kane N; Diaz-Perez S; Ganapathy E; Nazarian R; Felix C; Mathis C; Bradley M; Sachdeva A; Wyatt B; Basehart V; Zomorodian N; Lin L; King CR; Kupelian PA; Rettig MB; Steinberg ML; Cao M; Knudsen BS; Elashoff D; Schaue D; Reiter RE; Nickols NG
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):930-935. PubMed ID: 32562839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.